Patients of COVID-19 associated AKI may not have long-term kidney function decline: JAMA

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-03-01T05:00:18+05:30 | Updated On 1 March 2024 11:05 AM IST

A recent study unveiled the long-term consequences of COVID-19 with encouraging news for survivors of COVID-19-associated acute kidney injury (COVID-AKI). The study was published in the Journal of American Medical Association highlighted the lingering effects on kidney function in patients who battled COVID-19.

The retrospective longitudinal multicenter cohort study spanned from March 2020 to June 2022 and analyzed electronic health records of adult hospitalized patients with AKI by comparing the outcomes between those with COVID-19 and influenza-related AKI, as well as AKI from other causes. The study followed up with patients for up to two years post-discharge to assess the incidence of major adverse kidney events (MAKE), including mortality and the worsened kidney function.

The results of this study were from the analysis of 9624 hospitalized patients, including 987 with COVID-AKI. Despite initial concerns regarding the impact of COVID-19 on renal health, the survivors of COVID-AKI expressed lower rates of MAKE when compared to patients with AKI from other causes. The findings revealed a significantly lower risk of mortality and kidney function decline among the individuals who underwent COVID-19 by suggesting a more favorable long-term prognosis for kidney health in this cohort.

The study highlighted distinct demographic and clinical characteristics among patients with COVID-AKI, including a slightly younger age, higher baseline kidney function and more severe illness markers which indicates the unique challenges faced by this population. In summary, the findings of the study suggest that survivors of COVID-AKI may experience better long-term kidney function and lower mortality rates when compared to those with AKI from other causes that offers hope in the fight against the lasting impacts of the pandemic.

Source:

Aklilu, A. M., Kumar, S., Nugent, J., Yamamoto, Y., Coronel-Moreno, C., Kadhim, B., Faulkner, S. C., O’Connor, K. D., Yasmin, F., Greenberg, J. H., Moledina, D. G., Testani, J. M., & Wilson, F. P. (2024). COVID-19−Associated Acute Kidney Injury and Longitudinal Kidney Outcomes. In JAMA Internal Medicine. American Medical Association (AMA). https://doi.org/10.1001/jamainternmed.2023.8225

JAMA Internal MedicineCOVID-19 associated acute kidney injuryMajor adverse kidney events

Source : JAMA Internal Medicine

Jacinthlyn Sylvia

Neuroscience Masters graduate

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751